Given in escalating "dose" (number of pill)

Acetazolamide given in escalating doses
Acetazolamide: Subjects will begin with four 250 mg tablets daily.

Acetazolamide

Given in escalating "dose" (number of pill)
Placebo: Subjects will begin with four tablets daily.

Sugar Pill

Total

Sex: Female, Male

Race (NIH/OMB)

Weight

Body mass index is calculated as weight in kilograms divided by height in meters squared.

Body mass index

Weight change in the past 6 mo

Transient visual obscurations

Diplopia

Constant visual loss

Photophobia

Headache

Pulsatile tinnitus

Perimetric mean deviation is a measure of global visual field loss (mean deviation from age-corrected normal values), with a range of 2 to -32 dB; larger negative values indicate greater vision loss.

Perimetric mean deviation

Frisén papilledema grade is an ordinal scale that uses ocular fundus features to rate the severity of papilledema; grade 0 indicates no features of papilledema and grade 5 indicates severe papilledema.

Papilledema grade (fundus photography) Study Eye

Papilledema grade (fundus photography) Fellow eye

6-Item Headache Impact Test.
HIT-6 total score: 36-78 (higher scores indicate greater headache severity)

HIT-6 total score

CSF pressure

Generic health-related quality of life was assessed with the 36-Item Short Form Health Survey - SF-36 consists of eight scaled scores (vitality, physical functioning bodily pain, general health perceptions, physical role functioning, emotional role functioning, social role functioning, and mental health) : with weighted sums 0-100 (higher scores indicate better quality of life)

SF-36 component summary score

Treatment Effects on the Primary Outcome Variable, Mean change From Baseline to Month 6 in Perimetric Mean Deviation (PMD) in the Study Eye. Perimetric mean deviation is a measure of global visual field loss (mean deviation from age-corrected normal values), with a range of 2 to -32 dB; larger negative values indicate greater vision loss.

Mean Change in Perimetric Mean Deviation

Mean change at month 6 as compared to baseline. Frisén papilledema grade is an ordinal scale that uses ocular fundus features to rate the severity of papilledema; grade 0 indicates no features of papilledema and grade 5 indicates severe papilledema.

Mean Change of Papilledema Grade on Fundus Photography

Visual Function Questionnaire (VFQ-25) total score, VFQ-25 10-item neuro-ophthalmic supplement total score: 0-100 (higher scores indicate better quality of life)

Visual Function Questionnaire (VFQ-25)

Visual Acuity (No. of Correct Letters)

Overall Study

Dr. Michael Wall

Idiopathic Intracranial Hypertension

Subjects will begin with four 250 mg tablets daily. Tablets will be divided among two doses, taken with meals. Beginning on day 7, subjects will increase the dose by 1 pill every week until 16 tablets daily is reached (4 grams acetazolamide or placebo) or side effects prohibit increasing the dosage further. Thus, subjects who are able to tolerate the study medication will reach the maximum dose by day 84.

Subjects will begin with four tablets daily. Tablets will be divided among two doses, taken with meals. Beginning on day 7, subjects will increase the dose by 1 pill every week until 16 tablets daily is reached (4 grams acetazolamide or placebo) or side effects prohibit increasing the dosage further. Thus, subjects who are able to tolerate the study medication will reach the maximum dose by day 84.

Placebo

Teleconference, web-based from central location, using site visits and subject self-assessment tools

Formal weight loss counselling program

University of Alabama Birmingham

Doheny Eye Center, University of Southern California

The Eye Care Group, PC

Bascom Palmer Eye Institute, University of Miami

Neuro-Ophthamology & Balance Disorders Clinic

Emory University

University of Illinois

Department of Ophthamology and Visual Sciences, University of Iowa

University of Kentucky

Louisiana State University Health Sciences Center - Earl K. Long Medical Center

Greater Baltimore Medical Center Department Of Ophthamology

Johns Hopkins Universtiy - Wilmer Ophthamological Institute

Bethesda Neurology, LLC

Massachusetts Eye and Ear Infirmary - Neuro-Ophthamology Service

Michigan State University Department of Neurology

William Beaumont Hosptial Research Institute

University of Minnesota

Saint Louis University Eye Institute

University of St. Louis

New Jersey Medical School/University Physicians Associates of New Jersey

New York Eye and Ear Infirmary

Weill Cornell Medical College

The Mount Sinai Medical Center

University of Rochester - Flaum Eye Institute

Stony Brook University

SUNY Upstate Medical University, Neurology Medical Service Group

Duke Eye Center

Raleigh Neurology Associates, PA

Wake Forrest University Eye Center

Ohio State University

Dean A. McGee Eye Institute

Oregon Health & Science University - Casey Eye Institute

University of Pennsylvania, Department of Ophthamology

The Methodist Hospital: Methodist Eye Associates

Universtiy of Houston - University Eye Institute

University of Texas Science Center

University of Utah, John A. Moran Eye Center

University of Virginia - Department of Ophthalmology

Swedish Medical Center

University of Calgary: Rockyview General Hospital

Queen's University - Hotel Dieu Hospital

Idiopathic Intracranial Hypertension Treatment Trial

A Multicenter, Double-blind, Randomized, Placebo-controlled Study of Weight-Reduction and/or Low Sodium Diet Plus Acetazolamide vs Diet Plus Placebo in Subjects With Idiopathic Intracranial Hypertension With Mild Visual Loss

arteriovenous malformations/سمنة

Idiopathic Intracranial Hypertension Treatment Trial

قاعدة بيانات الأعشاب الطبية الأكثر اكتمالا التي يدعمها العلم